Imaging Cytometry Edge Amnis specializes in high-throughput imaging flow cytometry with capabilities to capture 12 high-resolution cell images per event at speeds up to 5,000 cells per second, presenting a compelling value proposition for biotech labs seeking advanced single-cell analysis.

Patented Competitive Advantage With over 50 issued US and international patents protecting their imaging platforms, Amnis offers a defensible technology position that can appeal to researchers and institutions seeking differentiated cytometry solutions and long-term IP protection.

Strategic Ownership History Having been owned by Merck Millipore and later sold to Luminex, Amnis sits within a broader life sciences ecosystem, creating potential alignment opportunities with distributors, integrators, and customers already engaged with Luminex or MilliporeSigma channels.

Revenue Signals Current revenue range of one to ten million indicates a small-to-mid market footprint with room for growth through expanded product adoption, channel partnerships, and cross-sell of imaging capabilities to traditional flow cytometry users.

Technical Fit for Labs Tech stack and platform branding suggest compatibility with lab environments that adopt modern web-enabled tools and imaging-based analytics, presenting opportunities to upsell training, software modules, and service contracts to educational and research institutions.